Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | AGTR2 | P50052 | 8/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.40 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.40 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21881815 | 0.90 | HPGD (0.46) | PTPN1AGTR2AGTR1PTGER4PTGER3 | |
| SCHEMBL21881520 | 0.90 | HPGD (0.46) | PTPN1AGTR2AGTR1PTGER4PTGER3 | |
| SCHEMBL21881909 | 0.89 | KDM4E (0.49) | PTPN1AGTR2PTGER4PTGER3PTGER2 | |
| SCHEMBL17772600 | 0.87 | AGTR2 (0.53) | AGTR2AGTR1 | |
| SCHEMBL421422 | 0.86 | AGTR2 (0.56) | AGTR2AGTR1 | |
| SCHEMBL433767 | 0.86 | AGTR2 (0.56) | AGTR2AGTR1 | |
| Hydrochloric Acid SCHEMBL23780713 | 0.85 | AGTR2 (0.55) | AGTR2AGTR1 | |
| Hydrochloric Acid SCHEMBL23780714 | 0.85 | AGTR2 (0.55) | AGTR2AGTR1 | |
| SCHEMBL17772592 | 0.85 | AGTR2 (0.40) | AGTR2AGTR1 | |
| SCHEMBL21881814 | 0.79 | AGTR2 (0.48) | AGTR2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9162985-B2 | Salts and solvates of a tetrahydroisoquinoline derivative | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2015-10-20 | — | — | US | disclosed |
| US-20150105422-A1 | SALTS AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2015-04-16 | — | — | US | disclosed |
| US-8927575-B2 | Salts and solvates of a tetrahydroisoquinoline derivative | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2015-01-06 | — | — | US | disclosed |
| US-20140080865-A1 | SALTS AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2014-03-20 | — | — | US | disclosed |
| US-20120022101-A1 | SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | SPINIFEX PHARMACEUTICALS PTY LTD, (AU) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080865-A1 | SALTS AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | SUDS3, REN, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PTPN1 2719/4885AGTR2 126/4885AGTR1 181/4885 |
| US-20120022101-A1 | SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | REN, SUDS3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PTPN1 2415/4885AGTR2 75/4885AGTR1 97/4885 |
| US-20150105422-A1 | SALTS AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | SUDS3, REN, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PTPN1 2719/4885AGTR2 126/4885AGTR1 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.